ABEONA THERAPEUTICS INC.
Data quality: 100%
ABEO
Nasdaq
Manufacturing
Chemicals
$4.91
▼
$0.21
(-4.10%)
Mkt Cap: 294.66 M
Price
$5.17
Mkt Cap
294.66 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—
Quick Summary
Key Takeaways
Revenue grew 18.02% annually over 5 years — strong growth
ROE of 42.52% indicates high profitability
Net margin of 1223.08% shows strong profitability
Debt/Equity of 0.12 — conservative balance sheet
Negative free cash flow of -84.30 M
P/E of 4.14 — trading at a low valuation
Growth
Revenue Growth (5Y)
18.02%
Above sector avg (1.82%)
Revenue (1Y)66.29%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
42.52%
Above sector avg (-53.34%)
ROIC-42.47%
Net Margin1223.08%
Op. Margin-1536.91%
Safety
Debt / Equity
0.12
Below sector avg (0.31)
Current Ratio9.74
Interest Coverage-23.92
Valuation
PE (TTM|2027)
4.14 | 21.54
Above sector avg (-1.47)
P/B Ratio1.72
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 4.1 | -1.5 |
| P/B | 1.7 | 1.6 |
| ROE % | 42.5 | -53.3 |
| Net Margin % | 1223.1 | -41.5 |
| Rev Growth 5Y % | 18.0 | 1.8 |
| D/E | 0.1 | 0.3 |
Analyst Price Target
7 analysts
Buy
Current
$4.91
Target
$19.57
$13.00
$20.00
$28.00
Forecast
Forward P/E
20.46
Forward EPS
$0.24
Est. Revenue
145.72 M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2027 |
$0.24
-$0.21 – $0.63
|
145.72 M | 3 |
| FY2026 |
-$0.91
-$1.05 – -$0.79
|
66.43 M | 3 |
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| 2026 Q2 |
-$0.29
-$0.32 – -$0.26
|
14.28 M | 3 |
| 2026 Q1 |
-$0.39
-$0.40 – -$0.38
|
4.94 M | 3 |
Earnings Surprises
Last 4 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| Q42025 | -$0.37 | -$0.37 | +2.2% |
| Q32025 | -$0.34 | -$0.11 | +68.5% |
| Q22025 | -$0.39 | -$0.47 | -19.0% |
| Q12025 | -$0.35 | -$0.24 | +32.2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 66.29% | Revenue Growth (3Y) | 28.95% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 18.02% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 5.82 M | Net Income (TTM) | 71.18 M |
| ROE | 42.52% | ROA | 29.83% |
| Gross Margin | N/A | Operating Margin | -1536.91% |
| Net Margin | 1223.08% | Free Cash Flow (TTM) | -84.30 M |
| ROIC | -42.47% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.12 | Current Ratio | 9.74 |
| Interest Coverage | -23.92 | Asset Turnover | 0.02 |
| Working Capital | 193.95 M | Tangible Book Value | 171.23 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 4.14 | Forward P/E | N/A |
| P/B Ratio | 1.72 | P/S Ratio | 50.63 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -28.61% | ||
| Market Cap | 294.66 M | Enterprise Value | 231.53 M |
| Per Share | |||
| EPS (Diluted TTM) | 1.01 | Revenue / Share | 0.10 |
| FCF / Share | -1.48 | OCF / Share | -1.34 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 137.03% | FCF Conversion | -118.43% |
| SBC-Adj. FCF | -94.33 M | Growth Momentum | 48.27 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.82 M | 3.50 M | 3.50 M | 1.41 M | 3.00 M |
| Net Income | 71.18 M | -63.73 M | -54.19 M | -39.70 M | -84.94 M |
| EPS (Diluted) | 1.01 | -1.55 | -2.53 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -89.45 M | -64.21 M | -47.14 M | -50.92 M | -89.84 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 26.81 M | 34.36 M | 31.09 M | 28.97 M | 34.33 M |
| SG&A Expenses | 65.03 M | — | — | — | — |
| D&A | 2.55 M | 2.00 M | 2.29 M | 3.09 M | 3.25 M |
| Interest Expense | 3.74 M | 4.21 M | 418,000.0 | 736,000.0 | 3.67 M |
| Income Tax | 100,000.0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 219.57 M | 108.93 M | 64.00 M | 64.21 M | 79.59 M |
| Total Liabilities | 60.35 M | 64.90 M | 49.18 M | 37.45 M | 28.21 M |
| Shareholders' Equity | 159.22 M | 44.03 M | 14.83 M | 26.76 M | 51.38 M |
| Total Debt | 20.04 M | 18.96 M | — | — | — |
| Cash & Equivalents | 78.44 M | 23.36 M | 14.47 M | 14.22 M | 32.94 M |
| Current Assets | 204.91 M | 100.85 M | 55.74 M | 53.10 M | 55.40 M |
| Current Liabilities | 29.57 M | 16.59 M | 13.42 M | 7.78 M | 16.62 M |
{"event":"ticker_viewed","properties":{"ticker":"ABEO","listing_kind":"stock","pathname":"/stocks/abeo","exchange":"Nasdaq","country":"US"}}
